MAP3K2 and cancer: Indeed, it interacts with and methylates several non-histone proteins (e.g., VEGFR1, HSP90, H2A.Z.1, MAP3K2, AKT1, ER, HER2), through which it activates specific pathways involved in the survival and proliferation of cancer cells [3], [22], [23], [24], [25], [26], [27].